相关实验视频
Updated: Sep 19, 2025

05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
4.8K
癌症治疗引起的心脏毒性:机制和缓解措施
Solanki Shil1, Prabodh Kumar2, Kamalesh Dattaram Mumbrekar3
1Department of Radiation Biology and Toxicology, Manipal School of Life Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India, 576104.
Heart failure reviews
|June 7, 2025
概括
癌症疗法可能会损害心脏,导致严重的疾病. 心脏瘤学提供心脏保护策略来减轻这些风险,改善癌症治疗期间和之后的患者结果.
科学领域:
- 心脏瘤学 - 心脏瘤学
- 心血管医学 心血管医学
- 在瘤学瘤学.
背景情况:
- 化学疗法,放射疗法和免疫疗法等癌症治疗可以改善存活率,但往往会导致心脏毒性.
- 这种心脏毒性影响临床结果,影响心肌细胞和内皮细胞,导致心肌重塑和血管功能障碍.
- 渐进的损伤可能导致诸如心肌病,心律失常,心力衰竭和突然心脏死亡等疾病.
研究的目的:
- 审查主要的癌症疗法及其心脏毒性机制.
- 在心脏瘤学领域详细介绍各种心脏保护策略.
- 通过减轻癌症治疗对心血管的不良影响来改善患者的治疗结果.
主要方法:
- 关于癌症治疗及其心脏毒性作用的文献综述.
- 对心脏毒性的细胞和分子机制的分析.
- 目前和新兴心脏保护策略的汇编.
主要成果:
- 化疗,放射治疗和免疫治疗诱导细胞应激,DNA损伤和心脏细胞的炎症.
- 心脏毒性导致心肌细胞损失,纤维化和病理性心肌重塑.
- 内皮损伤增加了动脉样硬化,冠状动脉疾病和缺血的风险.
结论:
- 心脏瘤学整合了药理学,诊断,自然化合物和生活方式干预措施,以进行心脏保护.
- 多方面的策略对于在癌症治疗期间和之后管理心脏毒性至关重要.
- 有效的心脏保护对于改善癌症患者的长期生存和生活质量至关重要.
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Heart Failure Drugs: Inotropic Agents
747
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
747
Adaptive Mechanisms in Cancer Cells
6.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Electron Transport Chain: Complex I and II
15.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
526
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
526

